Compare Boston Scientific Corporation (BSX) vs Johnson Controls International PLC (JCI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boston Scientific Corporation vs Johnson Controls International PLC — how do they compare? Boston Scientific Corporation trades at $51.07 (market cap $74.19B), while Johnson Controls International PLC trades at $153.94 (market cap $93.74B). The key difference: Johnson Controls International PLC is the larger of the two by market cap, and Johnson Controls International PLC pays a 1.03% dividend while Boston Scientific Corporation pays none. Which is the better fit depends on your goals.
| BSX | JCI | |
|---|---|---|
Market Cap | $74.19B | $93.74B |
Sector | Health | Industrials |
52-Week High | $108.14 | $154.76 |
52-Week Low | $42.63 | $103.52 |
Enterprise Value | $86.27B | $102.58B |
Dividend Yield | — | 1.03% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BSX trades at $50.46, up 2.33% today, with strong earnings beats in recent quarters and a bullish technical trend. Revenue grew to $20.07B in 2025, with net income margin expanding to 17.5%. The stock shows robust institutional support and insider buying, while facing near-term headwinds from competitive pressures in key segments like WATCHMAN.
Outlook remains positive with 86% analyst buy ratings and a $67.21 consensus price target, implying 33% upside. Risks include guidance cuts and market share losses, but solid cash flow and valuation metrics support long-term growth potential for patient investors.
JCI trades at $150.70, down 0.99% on the day, with a strong bullish technical signal from moving averages. The company reported robust Q3 2026 earnings, beating estimates with $1.42 EPS and raising full-year guidance, driven by double-digit organic sales growth and record backlog. Analyst consensus is strongly positive with a $168.25 price target and no sell ratings. Recent news highlights efficiency leadership and AI-related thermal management innovations.
The outlook remains favorable given earnings momentum and strategic positioning in high-demand sectors like data centers. Key risks include execution on growth targets and macroeconomic sensitivity. The stock presents a growth opportunity supported by fundamental strength and bullish sentiment, though valuation multiples are elevated.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →About Johnson Controls International PLC
Johnson Controls manufactures, installs, and services HVAC systems, building management systems and controls, industrial refrigeration systems, and fire and security solutions. Commercial HVAC accounts for about 40% of sales, fire and security also represents 40% of sales, and residential HVAC, industrial refrigeration, and other solutions account for the remaining 20% of revenue. In fiscal 2021, Johnson Controls generated over $23.5 billion in revenue.
Read more on JCI →
